24 April 2018 I Report and related presentation materials are available here.
26 Feb 2018 I Orion's Financial Statement documents for 2017 are published, and include Financial Statements, the report of the Board of Directors and the Auditor's report.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
From the sustainability section you will find, among others, our Sustainability reports, Code of Conduct and Quality Policy.
